Colonics
About Me
Recent Posts
- 'Personality Genes' May Help Account For Longevity
- 4 Mushroom Poisonings In 2 Weeks - Doctors Test Milk Thistle As Treatment
- Improved Diagnostics For Sleeping Sickness
- Prostate Growth May Be Slowed By Statins
- New Tools For Psychological Science Research - Facebook And Smartphones
Menu
Calendar
| Mon | Tue | Wed | Thu | Fri | Sat | Sun |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 | |||
Friends
Links
Entry 1 of 2381
Last Page | Next Page
4/12/2009
-
IntelGenx Corp. And Cary Pharmaceuticals File NDA For CPI-300 Antidepressant
|
IntelGenx Corp. (TSX:IGX)(OTCBB:IGXT) ("IntelGenx") and Cary Pharmaceuticals Inc. ("Cary Pharma") today announced that a New Drug form ("NDA") has been submitted to the U.S. Food and Drug patronage ("FDA") for their antidepressant CPI-300, a new strengthen of a leading antidepressant that will provide a more good dosing option to line with major bipolar illness jumble ("MDD"). More: - Continued here |
Post A Comment! :: Send to a Friend! |
Share and enjoy
